Journal
NANOMEDICINE
Volume 11, Issue 1, Pages 81-100Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nnm.15.188
Keywords
immune response; nano-bio interface; nanomedicine; nanoparticles; protein corona; targeting; toxicity
Funding
- Italian Ministry of Health [RF-2010-2318372, RF-2010-2305526]
- NIH/NCI [1R21CA173579-01A1]
- Pilot project from NIH/NCI [5U54CA143837 PSOC]
- BCRP Innovator Expansion from Department of Defence [W81XWH-12-10414]
- Regenerative Medicine Program Cullen Trust for Health Care
- POR Campania FSE Project DIAINTECH, Italy
- NATIONAL CANCER INSTITUTE [U54CA143837, R21CA173579] Funding Source: NIH RePORTER
Ask authors/readers for more resources
In a perfect sequence of events, nanoparticles (NPs) are injected into the bloodstream where they circulate until they reach the target tissue. The ligand on the NP surface recognizes its specific receptor expressed on the target tissue and the drug is released in a controlled manner. However, once injected in a physiological environment, NPs interact with biological components and are surrounded by a protein corona (PC). This can trigger an immune response and affect NP toxicity and targeting capabilities. In this review, we provide a survey of recent findings on the NP-PC interactions and discuss how the PC can be used to modulate both cytotoxicity and the immune response as well as to improve the efficacy of targeted delivery of nanocarriers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available